Plague vaccine - Biologic Drug Details

Summary for plague vaccine

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for plague vaccine Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for plague vaccine Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for plague vaccine Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for the Plague Vaccine

Last updated: March 9, 2026

What is the current market status for plague vaccines?

The market for plague vaccines remains niche, primarily driven by bioterrorism concerns, bioweapons defense strategies, and occasional endemic outbreaks. No licensed, widely distributed vaccine exists for general public use; available options are limited to research or military applications.

Two main candidate vaccines dominate the landscape: FRASCATI and VAMENGCO—both under development or limited in use. Currently, the U.S. Defense Threat Reduction Agency (DTRA) funds vaccine development efforts, signaling ongoing interest but limited commercial viability.

The global market value is estimated at under USD 50 million, consisting mostly of government and military contracts. Limited commercial sales exist outside research and defense sectors, constraining the overall market size.

Who are the key players developing plasmodium vaccines?

• CureVac/ABVI: Developing mRNA-based plague vaccines targeting Yersinia pestis.
• United States government agencies: DTRA, CDC, support early-stage vaccine development.
• Academic collaborations: Universities and research institutes exploring novel vaccine platforms.

Private biopharma firms have minimal active pipelines, typically focusing on biodefense rather than broad commercial markets.

What are the primary market drivers?

• Biodefense investments: US government funding prioritizes preparedness against bioweapons.
• Bioterrorism risk perception: Governments maintain stockpiles as a precaution.
• Rare outbreak events: Occasional infections, mostly in Africa and Asia, support localized vaccination programs.

Public health markets do not significantly contribute to demand due to the low incidence and lack of widespread licensed vaccines.

What are the key barriers impacting market growth?

• Limited demand: The rarity of natural infection reduces broad market potential.
• Safety/effectiveness concerns: Past vaccines faced adverse reactions or incomplete immunity.
• Regulatory challenges: No standard licensure pathway exists, complicating approval.
• Research and development costs: High costs with uncertain commercial returns hinder investment.

How does the regulatory environment influence the market?

The key regulatory pathway involves the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). For bioweapons vaccines, the FDA’s Animal Rule allows approval based on efficacy in animal models, but this applies primarily to defense uses.

The pathway for civilian licensure is less clear; demonstrating safety and efficacy in humans remains a challenge, further restricting market expansion.

What is the financial outlook for plague vaccine development?

• Development costs: Estimated at USD 50–150 million per candidate, including preclinical and clinical phases.
• Funding sources: US government grants, military budgets, biodefense programs.
• Commercial prospects: Limited, barring breakthroughs leading to broader indications or licensure for public health use.
• Pricing strategy: Public procurement contracts typically set prices around USD 50–200 per dose, based on production and stockpiling needs.

Long-term profitability remains uncertain, with most investments driven by government budgets rather than commercial sales.

How might future market shapes evolve?

• Advances in platform technology: mRNA or vector-based approaches could reduce R&D costs and improve safety, expanding potential use cases.
• Global health initiatives: Should plague outbreaks increase, international organizations might prioritize development for endemic regions.
• Biodefense budget shifts: Changes in government defense priorities could alter funding flows, either expanding or constricting market activity.
• Licensure pathways: Development of clearer regulatory routes can accelerate approval processes and market entry.

Summary table

Aspect	Details
Market size (2022)	Under USD 50 million
Key players	US government agencies, academic groups, biotech startups
Cost per candidate	USD 50–150 million
Licensing pathway	Animal Rule, limited civilian licensure
Primary drivers	Biodefense, bioterrorism concerns, sporadic outbreaks
Barriers	Limited demand, regulatory hurdles, high R&D costs

Key Takeaways

• The plague vaccine market remains constrained, mainly driven by government and defense investments.
• Commercialization prospects are limited without breakthrough efficacy, safety, or broader indications.
• Development costs are high, but funding primarily comes from biodefense budgets rather than commercial revenues.
• Regulatory pathways are focused on bioweapons defense, not routine civilian use.
• Technological innovations could expand future market opportunities or reduce costs.

FAQs

1. What are the main challenges in developing a plague vaccine?
Safety concerns, regulatory approval complexity, high research costs, and limited commercial demand restrict development efforts.

2. Who funds the majority of plague vaccine research?
Primarily US government agencies, including DTRA, CDC, and military agencies.

3. Are there licensed plague vaccines available for public use?
No, existing candidates are mainly experimental or limited to government and military applications.

4. Could technological advances change the market landscape?
Yes, platform technologies such as mRNA could reduce costs and improve safety, potentially expanding use cases.

5. What is the outlook for the global market?
Limited growth expected unless major outbreak risks increase or broader indications are developed.

---

References
[1] U.S. Food and Drug Administration. (2019). Animal Rule implementation for biothreat pathogen vaccines.
[2] MarketWatch. (2022). Biodefense vaccine market analysis.
[3] GlobalData. (2021). Infectious disease vaccines pipeline report.